Evaxion Biotech A/S
EVAX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $1 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 4,480.8% | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -292.6% | -29,319.2% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -316% | -30,308.2% | – | – |
| EPS Diluted | -9.8 | -32.4 | -39.2 | -50.4 |
| % Growth | 69.8% | 17.3% | 22.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |